For the quarter ending 2025-09-30, AMLX had $166,625K increase in cash & cash equivalents over the period. -$30,392K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -34,386 | -77,350 |
| Stock-based compensation expense | 7,076 | 14,183 |
| Depreciation expense | 120 | 297 |
| Accretion of investment discounts, net | 1,243 | 3,226 |
| Other non-cash items | 0 | -264 |
| Accounts receivable, net | 30 | -345 |
| Interest receivable | 55 | -73 |
| Prepaid expenses and other current assets | 3,221 | -6,523 |
| Operating lease right-of-use assets | 336 | 1,099 |
| Other assets | 0 | -24 |
| Accounts payable | -33 | 338 |
| Accrued expenses | 1,095 | -6,484 |
| Inventory impairment and loss on firm purchase commitments | - | 0 |
| Operating lease liabilities | -27 | -1,158 |
| Net cash used in operating activities | -30,368 | -65,072 |
| Purchases of property and equipment | 24 | 28 |
| Purchases of investments | 58,740 | 142,637 |
| Proceeds from maturities of marketable securities | 64,000 | 122,000 |
| Net cash (used in) provided by investing activities | 5,236 | -20,665 |
| Proceeds from financings, net of issuance costs | 191,111 | 65,577 |
| Proceeds from exercise of stock options and rsus vesting | 2,659 | 1,042 |
| Withholding taxes paid on stock-based awards | 2,164 | 988 |
| Net cash provided by financing activities | 191,606 | 65,631 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | 151 | 805 |
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | 166,625 | -19,301 |
| Cash and cash equivalents at beginning of period | 78,837 | - |
| Cash and cash equivalents at end of period | 226,161 | - |
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)